Objective-Pulmonary embolism (PE) is a life-threatening manifestation of venous thromboembolism with a high recurrence rate after anticoagulation cessation. Recently, we have reported that prothrombotic clot phenotype in venous thromboembolism patients is associated with an increased risk of recurrent deep-vein thrombosis. Approach and Results-We tested whether abnormal clot properties are predictive of recurrent PE. We investigated 156 consecutive white patients aged 18 to 65 years after the first-ever provoked or unprovoked PE (n=89), with or without deep-vein thrombosis. Plasma fibrin clot permeability (K s ), turbidity measurements, calibrated automated thrombography, and efficiency of fibrinolysis using clot lysis time, maximum D-dimer levels, and rate of increase in D-dimer levels were evaluated at ≥3 months of anticoagulant therapy, at least 4 weeks since the anticoagulation withdrawal. The primary end point was recurrent PE during a median follow-up of 50 months. Recurrent PE was diagnosed in 23 (14.7%; 5%/ yr) patients. Recurrent PE was associated with formation of denser fibrin networks reflected by lower K s (P=0.007) and impaired fibrinolysis, as evidenced by prolonged clot lysis time (P=0.012) and reduced maximum rate of increase in D-dimer levels in the lysis assay (P=0.004). Patients with recurrent PE had higher plasma D-dimer (P<0.001) and thrombin peak (P=0.007) compared with the remainder, whereas turbidity measurements and maximum D-dimer levels did not differ in the recurrence. Multivariate model showed that independent predictors of recurrent PE were female sex, unprovoked venous thromboembolism, higher plasma D-dimer, reduced K s , and reduced maximum rate of increase in D-dimer levels in the lysis assay (all P<0.05). 
D
eep-vein thrombosis (DVT) and pulmonary embolism (PE) collectively referred to as venous thromboembolism (VTE) affect 1 to 3 per 1000 persons per year. 1 Acute PE is the most serious clinical presentation of VTE. The incidence for PE ranges from 29 to 78 per 100 000 persons per year, 2 causing annually >300 000 deaths in Europe alone. 3 The pathogenesis of PE is multifactorial and ≈30% of these episodes are of unknown cause. 2, 3 The cumulative incidence of late recurrence of VTE after withdrawal of anticoagulation has been reported to reach 13% at 1 year, 23% at 5 years, and 30% at 10 years. 4 Predictors of VTE recurrence that have been reported in previous studies include advanced age, obesity, male sex, active cancer, history of unprovoked VTE, PE or proximal DVT, elevated D-dimer levels after cessation of anticoagulation, antiphospholipid syndrome, antithrombin, protein C or protein S deficiency, pregnancy and duration of anticoagulant treatment <3 months. 5 The risk factors for PE, mostly combined with DVT, are largely derived from studies that have been performed among VTE patients. 4 Prediction of recurrent PE remains challenging. 6 The final step of blood coagulation is thrombin-mediated conversion of soluble fibrinogen into fibrin and formation of fibrin clot stabilized by factor (F)XIII and relatively resistant to lysis. A balance between clot formation and fibrinolysis regulates fibrin clot stability. Altered fibrin clot properties, which are largely determined by genetic and environmental factors, have been shown in patients who experienced venous and arterial thromboembolic episodes. 7 The so-called prothrombotic clot phenotype, encompassing compact and poorly lysable fibrin clots, has been shown not only in patients with myocardial infarction, ischemic stroke, and peripheral arterial disease but also in subjects after unprovoked VTE and their first-degree relatives. [7] [8] [9] There is currently great interest in whether measurement of fibrin clot parameters can predict recurrent thromboembolic events. We have shown recently that such clot phenotype predisposes to post-thrombotic February 2017 syndrome and recurrent DVT in patients with DVT. 10 We hypothesized that abnormal fibrin clot properties measured ex vivo in plasma after cessation of anticoagulation are predictive of recurrent PE.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. 
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Results
At Baseline
Baseline characteristics of PE patients are summarized in Tables 2 and 3) .
Follow-Up
The median follow-up was 50 months (range, 2-70 months), encompassing 577 patient-year. Recurrent PE was recorded in 23 (14.7%) patients, including 17 subjects (74%) after the unprovoked index episode. Median time since anticoagulation 
Recurrent PE
Recurrent PE, including 12 (52.2%) cases of isolated PE, was more common among women, subjects after unprovoked events with higher D-dimer and slightly lower fibrinogen concentrations after anticoagulation withdrawal (Table 1) . Patients with recurrent PE had increased thrombin generation, reflected by a shorter time to thrombin peak (−18%), higher peak thrombin (+18%) and higher endogenous thrombin potential (+4%). Four genetic polymorphisms studied did not affect the risk of PE recurrence, but higher incidence of factor (F)XIII Val34Leu polymorphism was observed in subjects with recurrent PE or DVT (Table 1) . Altered plasma fibrin clot properties after anticoagulation withdrawal, including lower fibrin clot permeability coefficient (K s , −7%), indicating formation of more compact clots, and impaired fibrinolysis as evidenced by reduced maximum rate of increase in D-dimer levels (D-D rate , −7%) and prolonged clot lysis time (CLT, +11%), were observed in patients who experienced PE during follow-up compared with those without recurrent PE (Table 4) . Scanning electron images of clots prepared from citrated plasma obtained from PE patients with and without recurrent PE showed tighter fibrin structure with thinner fibers and smaller pores in the former group ( Figure 1 ). Fibrin clot variables showed no associations with duration of anticoagulation and time since the index event (data not shown).
Predictors of Recurrent PE
Receiver operator characteristic analysis ( Figure 2) showed high accuracy for D-dimer, peak thrombin, K s , D-D rate , and Table 5 . The highest sensitivity (first-ever PE patients with or without DVT who are correctly identified as having recurrent PE during the follow-up; 70%-80%) was found for plasma D-dimer, peak thrombin and K s , with positive predictive values for PE recurrence of ≈90%.
Kaplan-Meier recurrence event-free curves showed that elevated D-dimer levels and peak thrombin, as well as 3 fibrin variables, ie, reduced K s and D-D rate and prolonged CLT, were the predictors of recurrent PE (Figure 3) . Table 6 shows risk factors for recurrent PE by Cox proportional hazard analysis for categorical variables based on optimal cutoffs (Tables I and II in the online-only Data Supplement). Univariate analysis showed that unprovoked VTE, D-dimer levels >339 ng/mL, peak thrombin >269 nmol/L, K s ≤6.9×10 -9 cm 2 , D-D rate ≤0.073 mg/L per minute, and CLT>79 minutes were associated with recurrent PE. In the multivariate model female sex, unprovoked VTE, increased D-dimer, reduced K s , and reduced D-D rate predicted PE recurrence.
PE recurrences were associated with unprovoked VTE, higher plasma D-dimer, higher thrombin generation potential, longer CLT, and lower D-D rate (all P<0.05) in the univariate models (Table 7) . Multivariate analysis showed that female sex, higher plasma D-dimer and peak thrombin, and lower K s were associated with higher risk of recurrent PE (all P<0.05). Unprovoked VTE and CLT were no longer associated with recurrent VTE.
Discussion
To our knowledge, the current study shows that prothrombotic fibrin clot phenotype, including poorly permeable fibrin networks resistant to lysis, could be a novel risk factor for PE recurrence in subjects who discontinued anticoagulant therapy after the first episode of provoked or unprovoked PE. These differences cannot be explained by fibrinogen concentrations. It might be speculated that fibrin-related parameters have a prognostic role in PE patients who stopped anticoagulant therapy and they could help identify young or middle-aged subjects at risk of recurrent PE during a 4-year follow-up. However, factors that contribute to the unfavorably modified fibrin clot phenotype in patients with recurrent PE episodes remain to be established. Based on the literature, 7 it might be hypothesized that increased thrombin generation, lipoprotein (a), oxidative stress, and homocysteine can affect fibrin structure and function in PE patients. We showed that lower values of K s , a measure of fibrin structure indicating an average size of pores in the fiber networks, were independently associated with a higher risk of recurrent PE. Using 2 different approaches, we documented the association between impaired fibrinolysis and recurrent PE. These findings indicating a similar pattern of changes in fibrin characteristics as a predictor of recurrent PE and DVT 10 are surprising. Martinez et al 11 reported that clots made from plasma of patients with acute isolated PE were characterized by faster CLT and lower fiber density when compared with DVT alone. On the contrary, perfusion defects after PE and chronic thromboembolic pulmonary hypertension have been shown to be associated with impaired fibrinolysis. 12, 13 No data on clot properties after anticoagulation withdrawal or the risk of PE recurrence have been published to date. Unfavorably altered fibrin clot properties assessed in plasma were shown in patients after arterial embolization. 7, 14 It is well established that differences between the structure of fibrin clots and their functional characteristics might contribute to the clot fragmentation followed by pulmonary embolization. 7 The relative resistance of fibrin to lysis may be because of alterations in fibrin structure affecting accessibility to plasmin cleavage sites. 13 It is likely that formation of dense fibrin networks being less susceptible to even high concentrations of tissue-type plasminogen activator used in the lysis assay, in which D-D rate was determined, allows persistence of larger fragments of thrombotic material in circulating blood in the presence of the tendency to lower tissue-type plasminogen activator antigen in subjects with recurrent PE during follow-up. Increased thrombin generation after PE reported by us seems to mainly contribute to the formation of compact fibrin networks. 15 The links between fibrinolysis measured in global plasma-based lysis tests and VTE are inconsistent. Traby et al 16 demonstrated a weak association between CLT and VTE recurrences solely in women with unprovoked VTE. Meltzer et al 17 found no direct influence of CLT on the risk of VTE recurrence; however, because of wide ranges of CIs, this effect cannot be excluded. To our knowledge, no reports focused on CLT or other global lysis tests in patients with PE recurrence have been published to date.
Only 2 coagulation tests have been proposed for use after discontinuation of anticoagulant therapy to predict recurrent VTE episodes, that is, plasma D-dimer and thrombin generation. 18 We confirmed that elevated plasma D-dimer after anticoagulation withdrawal is a risk factor for PE recurrence. Moreover, our study supports the concept that thrombin generation reflected by the endogenous thrombin potential could be a promising indicator of risk for VTE recurrence as demonstrated by Eichinger et al. 19 To assess thrombin generation potential in our study, we used the maximum thrombin concentration, which is more sensitive to prothrombotic alterations than endogenous thrombin potential. 20 Our study showed that this variable also increases the risk of PE recurrence, suggesting its prognostic value in this clinical setting.
Several established and potential VTE risk factors were assessed with regard to PE recurrence in our study. In contrast to reports indicating up to 2-fold higher recurrence rate of VTE in men, 21 female sex was a risk factor for PE recurrence in the present study. However, no sex-related differences in VTE rates were observed in some studies, 22 and this issue remains controversial in particular in patients with PE. 23 Our study confirmed that in patients with unprovoked PE, the risk of recurrence is markedly higher than in those with provoked VTE, which agrees with other studies. 24 Elevated D-dimer after anticoagulation withdrawal also predicted PE recurrence in our study like in many others. 5, 6, 18, 19 Elevated CRP, indicating enhanced systemic inflammation, has been shown in patients at risk of VTE 25 ; however, we did not observe higher CRP in subjects with recurrent PE. The FXIII Val34Leu polymorphism, that accelerates thrombin-mediated FXIII activation and affects fibrin clot structure, 26 was more common in subjects with recurrent VTE, but not with PE alone.
This study has several limitations. First, our cohort was rather small and included patients during pregnancy or postpartum and patients with hereditary thrombophilia. Second, samples were drawn only once; therefore, we cannot excluded changes in fibrin clot properties over time. However, clot variables did not differ in the time from the index PE episode. Third, experiments in purified fibrinogen to get more insights into the mechanisms of the associations observed were beyond the scope of the current study. Moreover, patients free of any signs or symptoms of PE or DVT were not assessed by imaging, so asymptomatic VTE events could be omitted. Finally, we cannot extrapolate our findings to high-risk or elderly PE patients who were ineligible in this study. Recurrence prediction using available prediction models in elderly patients could be especially important because of higher risk of bleeding related to prolonged anticoagulation. 27 Strengths of this study include the prospective investigation of PE with assessment of several fibrin clot variables. This study is unique in its exploration of whether the plasma fibrin clot phenotype may affect the PE recurrence risk estimation.
To conclude, we demonstrated that abnormal plasma fibrin clot characteristics measured a few months since PE were associated with an increased risk of recurrent PE during longterm follow-up. It might be speculated that screening for prothrombotic fibrin clot phenotype in addition to D-dimer levels and thrombin generation may be clinically useful in identifying individuals at greatest risk of recurrent PE.
